In this article, we will be taking a look at the 12 Best Robinhood Stocks to Buy Under $10. 

Officially, Robinhood Markets is now a diversified financial behemoth rather than just a “meme-stock” brokerage. As of early 2026, the company is more than just a trading app; its record-breaking $4.5 billion in total net sales for the entire year 2025 shows that it is a key financial ecosystem for the next generation.

As of the end of February 2026, the US Robinhood market is characterized by massive asset inflows and a maturing user base. The platform reported total assets of $314.2 billion, reflecting a remarkable 68% growth compared to the previous year. Funded customers reached 27.4 million, showing steady growth even as the platform operates at a large scale. Additionally, net deposits hit a record $68 billion over the past twelve months, representing a 36% annual growth rate and indicating that users are increasingly moving their primary wealth, not just “play money”, onto Robinhood.

Robinhood Markets is aggressively shaping the US retail market through three primary pillars: Advanced Trading, Predictive Markets, and AI Integration. Following the strategic acquisition of a majority stake in MIAXdx (formerly LedgerX), Robinhood has significantly expanded its prediction markets business, trading record volumes of event contracts in 2025 and positioning itself for further growth in that segment.

Robinhood Markets has been improving its Legend platform with sophisticated tools, including futures, options, and professional-grade charting, in an effort to attract more experienced traders. This has led to ongoing growth in margin lending balances and other interest-earning assets. Simultaneously, real-time, user-friendly insights into market activity are being provided by AI-driven tools like Cortex and personalized portfolio digests, which assist in lowering the barrier to understanding complicated data and empower investors with actionable analysis.

With that said, let’s now take a look at the best Robinhood stocks.

Our Methodology

For our methodology, we selected stocks on the Robinhood app trading under $10 and limited our final selection to companies that have recently reported noteworthy developments likely to influence investor sentiment. These stocks are also popular among analysts and top hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is our list of the 12 best Robinhood stocks to buy under $10.

12. Health Catalyst, Inc. (NASDAQ:HCAT)

Number of Hedge Fund Holdings: 13

Share Price as of the Close of March 18: $1.17

Health Catalyst, Inc. (NASDAQ:HCAT) is one of the best Robinhood stocks on this list.

TheFly reported on March 18 that Wells Fargo lowered its rating on HCAT to Equal Weight from Overweight and slashed its price target from $5 to $1. According to the firm, recent sales and strategic adjustments are unlikely to boost performance in the near future, and revenue and margin issues are anticipated to persist through 2027. Noting that the corporation does not seem to have a clear short-term solution, Wells Fargo likewise lowered its projections.

Additionally, as part of its March 12 earnings announcement, Health Catalyst, Inc. (NASDAQ:HCAT) released its fiscal first quarter 2026 guidance along with results for the quarter and year that concluded on December 31, 2025. Alongside the announcement, management emphasized that, under CEO Ben Albert’s direction, it is concentrating on improving long-term execution and fixing operational flaws.

HCAT estimated that overall revenue for the first quarter of 2026 would be between $68 million and $70 million. Additionally, the business projected Adjusted EBITDA to be between $7 and $8 million. The release’s financial outlook portion contained the guidance, which represented management’s expectations for short-term business performance as it strives to enhance execution and set up the company for long-term success.

Health Catalyst, Inc. (NASDAQ:HCAT) is a healthcare data and analytics company that provides cloud-based software and professional services to help hospitals and health systems improve clinical, financial, and operational performance.

11. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holdings: 19

Share Price as of the Close of March 18: $8.56

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best Robinhood stocks on this list.

TheFly reported on March 11 that BTIG gave IBRX a Buy rating and assigned a $13 price target. The firm pointed to the stock’s strong performance in 2026, supported by rapid year-over-year growth in U.S. ANKTIVA sales, conditional marketing authorization in the European Union, and NSCLC approval in Saudi Arabia. BTIG also said additional upside could come from continued commercial progress for ANKTIVA and potential expansion of its approved uses.

Additionally, on March 13, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) announced it had completed its NK2022 and NK2023 manufacturing engineering programs, advancing a leukapheresis-to-production process for its autologous memory cytokine-enhanced natural killer cell therapy platform.

The company also said a Phase 1 study combining M-ceNK with ANKTIVA in relapsed or refractory tumor patients was completed and showed the treatment was well-tolerated after infusion.

Together, the programs enrolled 74 participants, including healthy donors and cancer patients, and produced key process development and robotic automation data for future clinical use. IBRX reported that 64 participants completed apheresis without serious procedure-related adverse events. In addition, 10 cancer patients received 23 doses, with no serious adverse events reported during treatment.

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotech company developing and commercializing immunotherapies, led by ANKTIVA, to treat cancer and infectious diseases by activating the body’s immune system.